Form 4: OrbiMed Affiliates Exercise Warrants in Corvus Pharmaceuticals, Increasing Stake

OrbiMed Private Investments V, LP, an affiliate of OrbiMed Advisors LLC, exercised common warrants to acquire 1,397,684 shares of Corvus Pharmaceuticals, Inc. common stock on a cashless basis.

Summary

• OrbiMed Private Investments V, LP (OPI V) exercised 1,397,684 common warrants of Corvus Pharmaceuticals, Inc. on June 27, 2025.
• The exercise price for the warrants was $3.50 per share.
• The exercise was conducted on a cashless basis, leading to the Issuer withholding 1,176,332 shares to cover the exercise price.
• As a result, OPI V received 221,352 net shares (1,397,684 exercised shares minus 1,176,332 withheld shares).
• Following the transaction, the indirect beneficial ownership of common stock by OrbiMed Advisors LLC and OrbiMed Capital GP V LLC is 7,165,006 shares.
• The warrants had an exercise price of $3.50, became exercisable on April 29, 2025, and expired on June 30, 2025.

Sentiment

Score: 7

Explanation: The exercise of warrants by a major institutional investor and 10% owner, OrbiMed, indicates continued confidence in Corvus Pharmaceuticals. Although a cashless exercise resulted in some shares being withheld, the net increase in shares held by the investor is a positive signal. The transaction is a routine event for expiring in-the-money warrants, but the continued commitment from a sophisticated investor is generally viewed favorably.

Positives

• Exercise of warrants indicates confidence from a significant investor (OrbiMed) in the company's future prospects, especially given the exercise price of $3.50 compared to the $4.1586 value of shares withheld.
• The transaction increases the direct shareholding of OrbiMed Private Investments V, LP by 221,352 shares.

Negatives

• The cashless exercise resulted in 1,176,332 shares being withheld by the Issuer, which means fewer new shares were issued than the total warrants exercised.

Future Outlook

NA

Industry Context

This Form 4 filing details an insider transaction by a major institutional investor, OrbiMed, in a pharmaceutical company. Such transactions are common in the biotech and pharmaceutical sectors, where venture capital and specialized investment firms often take significant stakes and board positions in developing companies. The exercise of warrants by a key investor like OrbiMed can be seen as a vote of confidence in Corvus Pharmaceuticals' long-term potential, aligning with typical investment strategies in the life sciences industry where long-term value creation is sought.

Related Party Transactions

• OrbiMed Private Investments V, LP, an affiliate of OrbiMed Advisors LLC (a 10% owner and entity with a director on the Issuer's board), exercised common warrants to purchase shares of Corvus Pharmaceuticals, Inc. This transaction constitutes a related party transaction due to OrbiMed's significant ownership and board representation.

Stakeholder Impact

• Shareholders: The exercise of warrants by a major institutional investor could be perceived as a positive signal, potentially boosting investor confidence. The cashless exercise mechanism means fewer new shares were issued than if the exercise was fully cash-based, limiting immediate dilution from this specific transaction. The overall beneficial ownership by OrbiMed remains substantial, indicating continued alignment with long-term shareholder interests.

Key Dates

Recommendation

Keywords

Corvus Pharmaceuticals, CRVS, OrbiMed Advisors, OrbiMed Capital GP V LLC, OrbiMed Private Investments V LP, SEC Form 4, Warrant Exercise, Beneficial Ownership, Insider Transaction, Equity Securities, Cashless Exercise, Investment Management